This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ampio Pharmaceuticals Leases New Facility In Denver Tech Center





GREENWOOD VILLAGE, Colo., Dec. 16, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the ten-year lease of a multi-purpose facility located in the Denver Tech Center of Colorado. Renovation, beginning in early 2014, will provide commercial scale, FDA compliant, State-of-the Art, GMP manufacturing of Ampion and an advanced Research and Development Laboratory as well as sufficient office space to consolidate all operations of the company in a single facility. These renovations will require approximately $7 million in capital expenditures previously accounted for.

(Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

"This investment demonstrates Ampio's commitment to address the potential demand for Ampion from the approximately twenty million sufferers of osteoarthritis-of-the-knee in the United States," said Michael Macaluso, Chairman and CEO of Ampio.  "Ampion is one of the most important drugs in our portfolio, protected by 45 issued patents and 40 pending, covering multiple clinical indications, manufacturing processes, synthetic methods, and composition of matter claims. As it is our goal to establish Ampio as a global leader in the treatment of inflammatory diseases, the full and timely operation of this new facility that will manufacture our lead drug is a necessary step along that path. The facility renovation is scheduled to begin in the first quarter of 2014 and is expected to be completed in the summer of 2014."

Dr. Vaughan Clift, Chief Regulatory Officer of Ampio, noted, "The manufacturing facility will initially provide registration batches of Ampion for the Biologic License Application (BLA). Once the manufacturing operation is approved by the FDA for commercial production, the facility will have an annual production capacity of approximately ten million of the 4 mL doses and more than 50% of the raw material, (human serum albumin, HSA) required to meet this capacity has already been secured through a long-term, non-exclusive, supply agreement as previously announced. The pharmaceutical drug manufacturing group that has produced the Ampion™ clinical supplies to date is overseeing this project until the facility is fully operational."



1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs